These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 12823153

  • 1. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL.
    Aliment Pharmacol Ther; 2003 Jun 15; 17(12):1507-14. PubMed ID: 12823153
    [Abstract] [Full Text] [Related]

  • 2. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K, Lind T, Wilder-Smith C.
    Eur J Clin Pharmacol; 2004 Oct 15; 60(8):531-9. PubMed ID: 15349707
    [Abstract] [Full Text] [Related]

  • 3. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct 15; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 4. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P, Katz PO, Chen Y, Sostek M.
    Am J Gastroenterol; 2003 Dec 15; 98(12):2616-20. PubMed ID: 14687806
    [Abstract] [Full Text] [Related]

  • 5. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
    Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, van Milligen de Wit AW, de Groot GH, Dutch omeprazole MUPS study group.
    Eur J Gastroenterol Hepatol; 2002 Jun 15; 14(6):649-56. PubMed ID: 12072599
    [Abstract] [Full Text] [Related]

  • 6. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
    Williams MP, Usselmann B, Chilton A, Sercombe J, Nwokolo CU, Pounder RE.
    Aliment Pharmacol Ther; 2003 Mar 15; 17(6):775-83. PubMed ID: 12641499
    [Abstract] [Full Text] [Related]

  • 7. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
    Hartmann M, Theiss U, Huber R, Lühmann R, Bliesath H, Wurst W, Lücker PW.
    Aliment Pharmacol Ther; 1996 Jun 15; 10(3):359-66. PubMed ID: 8791964
    [Abstract] [Full Text] [Related]

  • 8. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan 15; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS, Berardi RR.
    J Am Pharm Assoc (Wash); 2000 Jan 15; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [Abstract] [Full Text] [Related]

  • 10. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.
    Florent C, Forestier S.
    Eur J Gastroenterol Hepatol; 1997 Feb 15; 9(2):195-200. PubMed ID: 9058634
    [Abstract] [Full Text] [Related]

  • 11. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Tazuma S, Horikawa Y, Nakamura M.
    Dig Dis Sci; 2005 Jul 15; 50(7):1202-6. PubMed ID: 16047460
    [Abstract] [Full Text] [Related]

  • 12. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct 15; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 13. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Kromer W.
    Scand J Gastroenterol Suppl; 2001 Oct 15; (234):3-9. PubMed ID: 11768559
    [Abstract] [Full Text] [Related]

  • 14. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP, Sercombe J, Hamilton MI, Pounder RE.
    Aliment Pharmacol Ther; 1998 Nov 15; 12(11):1079-89. PubMed ID: 9845397
    [Abstract] [Full Text] [Related]

  • 15. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ, Andersson TB, Ahlström M, Weidolf L.
    Drug Metab Dispos; 2004 Aug 15; 32(8):821-7. PubMed ID: 15258107
    [Abstract] [Full Text] [Related]

  • 16. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
    Huang JQ, Goldwater DR, Thomson AB, Appelman SA, Sridhar S, James CF, Chiu YL, Pilmer BL, Keith RG, Hunt RH.
    Aliment Pharmacol Ther; 2002 Mar 15; 16(3):425-33. PubMed ID: 11876695
    [Abstract] [Full Text] [Related]

  • 17. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
    Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, Delchier JC, Bonnot-Marlier S.
    Aliment Pharmacol Ther; 2004 Oct 15; 20(8):899-907. PubMed ID: 15479362
    [Abstract] [Full Text] [Related]

  • 18. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.
    Täubel JJ, Sharma VK, Chiu YL, Lukasik NL, Pilmer BL, Pan WJ.
    Aliment Pharmacol Ther; 2001 Nov 15; 15(11):1807-17. PubMed ID: 11683695
    [Abstract] [Full Text] [Related]

  • 19. What is potent acid inhibition, and how can it be achieved?
    Calvet X, Gomollón F.
    Drugs; 2005 Nov 15; 65 Suppl 1():13-23. PubMed ID: 16335854
    [Abstract] [Full Text] [Related]

  • 20. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
    Lew EA, Barbuti RC, Kovacs TO, Sytnic B, Humphries TJ, Walsh JH.
    Aliment Pharmacol Ther; 1998 Jul 15; 12(7):667-72. PubMed ID: 9701531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.